Biotech, Ebola, Life Sciences

AVI Gets Green Light for Ebola Trial

Luke Timmerman 12/24/08

AVI Biopharma, a Portland, OR-based drug developer, said it has “verbal clearance” from the FDA to start clinical trials against the deadly Ebola and Marburg viruses. AVI expects to get a formal written go-ahead from the FDA in early 2009, the company said. Shares of the company (NASDAQ: AVII) shot up 63 percent to 80 cents shortly after the opening bell.

Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.